The Trump administration "will take a look" after billionaire investor Peter Thiel said the FBI and CIA should see if Chinese intelligence has infiltrated Google.Technologyread more
On Monday, the first day of Amazon's 48-hour shopping extravaganza this year, retailers that make more than $1 billion in annual revenues saw a 64% increase in their digital...Retailread more
Builder confidence for single-family homes rose just one point to 65 in July, according to the National Association of Home Builders/Wells Fargo Housing Market Index (HMI)....Real Estateread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
Expectations for lower interest rates and less fear about tariffs sent investors back into the market and set up what could be a profitable run ahead.Marketsread more
A crop of long-awaited technology companies coming to the public market this year created a "frothy" period, Bernstein said on TuesdayInvestingread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Credit card sales volume rose 11% this quarter and merchant processing volume increased 12%, the bank says in its earnings statement.Banksread more
EU Competition Commissioner Margrethe Vestager is preparing to launch a full probe into Amazon in the coming days, Bloomberg reported.Technologyread more
IBM announced Tuesday that it signed a multi-year agreement with AT&T enabling the carrier to host its business applications on the IBM Cloud.Technologyread more
Amazon Prime Day enters its second day, with more than 1 million deals being offered, including intermittent "lightning deals." Here's how to navigate the 48-hour shopping...Invest in You: Ready. Set. Grow.read more
(Adds background, FDA's comments)
July 3 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer.
The drug Xpovio was approved in combination with dexamethasone for patients who have received at least four prior therapies and who fail to respond to certain other treatments, the agency said.
"Sadly, often over time, patients can exhaust all available treatments and still see their disease progress," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.
Karyopharm said it expects Xpovio to become commercially available in the United States by July 10.
The drug, chemically known as selinexor, binds to and inhibits a protein called XPO1, leading to the accumulation of cancer-suppressing proteins in the cells.
The U.S. health regulator was to initially decide on the treatment's approval in April, but pushed back the date by three months to review additional data submitted by the company.
Multiple myeloma is estimated to cause nearly 13,000 deaths in the United States in 2019, according to the American Cancer Society.
Shares of the company closed down 36% on Wednesday. (Reporting by Manojna Maddipatla and Manas Mishra in Bengaluru; Editing by Shailesh Kuber)